Bejelentkezés Regisztrálj ingyen

Last updated: 23 July 2021 at 5:18pm EST

Aradhana Sarin Net Worth




The estimated Net Worth of Aradhana Sarin is at least $10.5 millió dollars as of 21 June 2019. Ms. Sarin owns over 578 units of Alexion Pharmaceuticals stock worth over $5,529,199 and over the last 7 years she sold ALXN stock worth over $76,296. In addition, she makes $4,877,140 as Executive Vice President és Chief Financial Officer at Alexion Pharmaceuticals.

Ms. Sarin ALXN stock SEC Form 4 insiders trading

Aradhana has made over 1 trades of the Alexion Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 578 units of ALXN stock worth $76,296 on 21 June 2019.

The largest trade she's ever made was selling 578 units of Alexion Pharmaceuticals stock on 21 June 2019 worth over $76,296. On average, Aradhana trades about 41 units every 0 days since 2018. As of 21 June 2019 she still owns at least 30,201 units of Alexion Pharmaceuticals stock.

You can see the complete history of Ms. Sarin stock trades at the bottom of the page.





Aradhana Sarin biography

Aradhana Sarin M.D. serves as Executive Vice President, Chief Financial Officer of the Company. She is Executive Vice President, Chief Financial Officer of Alexion. In this role, she is responsible for overseeing global financial management, treasury, internal audit, corporate strategy, business development, investor relations, security activities, and business operations, including corporate planning, at Alexion. Dr. Sarin joined Alexion in November 2017 to drive strategy and business development, and she served as Alexion’s Chief Business and Strategy Officer prior to becoming the Chief Financial Officer in October 2019. She brings to Alexion more than 20 years of professional experience at global financial institutions. Dr. Sarin has extensive knowledge of global healthcare systems, and has closed more than 100 transactions across M&A, equity and debt financing transactions. Prior to joining Alexion, Dr. Sarin was Managing Director of Healthcare Corporate & Investment Banking at Citi Global Banking (which she joined in 2010), focusing on clients in the life sciences and biopharmaceutical sectors. Before this, she served as Managing Director of Healthcare Investment Banking at UBS, and worked at JP Morgan in the M&A Advisory and Healthcare groups focusing on transaction execution. Before her banking career, Dr. Sarin trained as a medical doctor in India and spent two years practicing in both India and Africa. Dr. Sarin also serves on the Board of OraSure Technologies, Inc., a manufacturer of point-of-care diagnostic tests. Dr. Sarin completed her medical training at the University of Delhi and received her MBA from Stanford Business School.

What is the salary of Aradhana Sarin?

As the Executive Vice President és Chief Financial Officer of Alexion Pharmaceuticals, the total compensation of Aradhana Sarin at Alexion Pharmaceuticals is $4,877,140. There are 3 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of $18,948,000.



How old is Aradhana Sarin?

Aradhana Sarin is 45, she's been the Executive Vice President és Chief Financial Officer of Alexion Pharmaceuticals since 2019. There are 16 older and no younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.

What's Aradhana Sarin's mailing address?

Aradhana's mailing address filed with the SEC is C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON, MA, 02210.

Insiders trading at Alexion Pharmaceuticals

Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell és Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.



What does Alexion Pharmaceuticals do?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



What does Alexion Pharmaceuticals's logo look like?

Alexion Pharmaceuticals Inc. logo

Complete history of Ms. Sarin stock trades at Alexion Pharmaceuticals és Orasure Technologies

Dátum
#
Cég
 Az érdekelt
Trans.
Tranzakció
 Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
21 Jun 2019 ALXN Alexion Pharmaceuticals Inc. Aradhana Sarin
EVP és CFO
 Eladás 578 $132.00 $76,296
21 Jun 2019
30,201 ↗


Alexion Pharmaceuticals executives and stock owners

Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: